These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 5647519)

  • 21. Purulent pericarditis in the antibiotic era.
    Gould K; Barnett JA; Sanford JP
    Arch Intern Med; 1974 Nov; 134(5):923-7. PubMed ID: 4155282
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical outcome of pneumococcal bacteremia, in vitro resistance, and antibiotic therapy.
    Torres-Tortosa M; Caballero-Granado J; Canueto J; Moreno-Maqueda I
    Clin Infect Dis; 2004 Mar; 38(5):763-4; author reply 765-6. PubMed ID: 14986265
    [No Abstract]   [Full Text] [Related]  

  • 23. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.
    Knudsen JD; Fuursted K; Raber S; Espersen F; Frimodt-Moller N
    Antimicrob Agents Chemother; 2000 May; 44(5):1247-54. PubMed ID: 10770759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Studies on josamycin. 3. (1) Bacteriological studies. (2) Protective effect against infections due to pathogenic bacteria. (3) Absorption, excretion, distribution in organs and in vivo activities].
    Osono T; Yano K; Mitamoto F; Watanabe S; Ishida H
    Jpn J Antibiot; 1969 Apr; 22(2):159-72. PubMed ID: 4389777
    [No Abstract]   [Full Text] [Related]  

  • 26. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid.
    Brook I; Foote PA; Hausfeld JN
    Int J Antimicrob Agents; 2005 Nov; 26(5):416-9. PubMed ID: 16226017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A54145 a new lipopeptide antibiotic complex: microbiological evaluation.
    Counter FT; Allen NE; Fukuda DS; Hobbs JN; Ott J; Ensminger PW; Mynderse JS; Preston DA; Wu CY
    J Antibiot (Tokyo); 1990 Jun; 43(6):616-22. PubMed ID: 2380110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antibacterial activity of a new 3-azinomethyl-rifamycin.
    Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
    Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Value of quantitative bacteriological examination of sputum in the evaluation of the effectiveness of chemotherapy of bacterial respiratory tract infections. I. Bacteriological studies].
    Przybyłkiewicz Z; Nikodemowicz E; Kasprowicz A; Owsiński J
    Pneumonol Pol; 1980 Aug; 48(8):535-43. PubMed ID: 6775309
    [No Abstract]   [Full Text] [Related]  

  • 31. [Strategies for management of resistant Gram-positive infections: from S. pneumoniae to MRSA].
    Cristini F
    Infez Med; 2007 Sep; 15 Suppl 2():13-9. PubMed ID: 17940408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Emergence of gram-positive organisms: causes, clinical significance and possibilities of control].
    García-Rodríguez JA; García Sánchez E
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():3-11. PubMed ID: 9441320
    [No Abstract]   [Full Text] [Related]  

  • 33. Albomycin is an effective antibiotic, as exemplified with Yersinia enterocolitica and Streptococcus pneumoniae.
    Pramanik A; Stroeher UH; Krejci J; Standish AJ; Bohn E; Paton JC; Autenrieth IB; Braun V
    Int J Med Microbiol; 2007 Oct; 297(6):459-69. PubMed ID: 17459767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bacterial hospitalism in the light of current knowledge on the origin and mechanism of antibiotic resistance].
    Lebek G
    Med Monatsschr; 1970 Apr; 24(4):142-5. PubMed ID: 5485956
    [No Abstract]   [Full Text] [Related]  

  • 35. Clindamycin (Dalacin C).
    Drug Ther Bull; 1970 Aug; 8(17):67-8. PubMed ID: 5480245
    [No Abstract]   [Full Text] [Related]  

  • 36. [Bacteriological study on methylthio-bromo-cinnamyl penicillin].
    Nakazawa S; Kanamori M; Nishino T; Miyakawa M
    Jpn J Antibiot; 1968 Apr; 21(2):68-71. PubMed ID: 5302423
    [No Abstract]   [Full Text] [Related]  

  • 37. Antibiotic susceptibility.
    Congeni B
    Pediatr Rev; 2009 Dec; 30(12):499-501. PubMed ID: 19952134
    [No Abstract]   [Full Text] [Related]  

  • 38. [Value of quantitative bacteriological examination of sputum in the evaluation of the effectiveness of chemotherapy of bacterial respiratory tract infections. II. Clinical studies].
    Nikodemowicz E; Owsiński J; Przybyłkiewicz Z; Kasprowicz A; Maternowska W; Kamińska M; Walaszek K; Prus F
    Pneumonol Pol; 1980 Aug; 48(8):545-22. PubMed ID: 6968434
    [No Abstract]   [Full Text] [Related]  

  • 39. A new antibiotic, josamycin. II. Biological studies.
    Nitta K; Yano K; Miyamoto F; Hasegawa Y; Sato T
    J Antibiot (Tokyo); 1967 Jul; 20(3):181-7. PubMed ID: 6072799
    [No Abstract]   [Full Text] [Related]  

  • 40. [Protective effect of stem-bromelain in combination with antibiotics on experimental infection in mice induced by Streptococcus hemolyticus, Diplococcus pneumoniae, or Pseudomonas aeruginosa (author's transl)].
    Ishikawa H; Oguro Y
    Jpn J Antibiot; 1974 Apr; 27(2):118-21. PubMed ID: 4152712
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.